Kaufman Rossin Wealth LLC Acquires Shares of 1,300 Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Kaufman Rossin Wealth LLC invested approximately $351,000 in Alnylam Pharmaceuticals, acquiring 1,300 shares in the first quarter of the year.
• Wall Street analysts have ramped up their price targets for Alnylam Pharmaceuticals, with firms like Needham & Company and JPMorgan increasing their estimates from $377.00 to as high as $570.00.
• Insider selling has occurred recently, with Director Dennis A. Ausiello selling 31,448 shares valued at over $13.7 million, indicating a significant reduction in ownership.

Kaufman Rossin Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,300 shares of the biopharmaceutical company's stock, valued at approximately $351,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after buying an additional 323,206 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after buying an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after purchasing an additional 185,783 shares during the period. American Century Companies Inc. grew its stake in shares of Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock worth $475,353,000 after purchasing an additional 156,411 shares during the period. Finally, Groupama Asset Managment grew its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 1st quarter. Groupama Asset Managment now owns 1,540,139 shares of the biopharmaceutical company's stock worth $415,868,000 after purchasing an additional 11,689 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 2.8%

ALNY traded down $13.17 on Friday, hitting $454.38. The company had a trading volume of 1,075,489 shares, compared to its average volume of 1,386,802. The firm has a market cap of $59.56 billion, a P/E ratio of -183.96 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $469.81. The company's fifty day moving average price is $360.65 and its 200 day moving average price is $296.84. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares of the company's stock, valued at approximately $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the sale, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 108,531 shares of company stock worth $41,087,238 over the last 90 days. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Bank of America raised their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a report on Friday, July 11th. HC Wainwright raised their price objective on Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Needham & Company LLC raised their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Finally, JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.